Common Sensing
Common Sensing is a Cambridge-based medical technology company founded in 2012 that develops and manufactures data-driven hardware and software solutions for patients using injectable medicines, with strategic backing from Philips, Sanofi Ventures, Qualcomm Ventures, and other healthcare investors.
- Company typePrivate
- Founded2012
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Common Sensing does
Common Sensing is a Cambridge, Massachusetts-based medical technology company founded in 2012 that develops and manufactures data-driven hardware and software solutions for patients using injectable medicines. The company operates at the intersection of connected drug delivery devices and patient-facing software, building physical injectors or sensors that interface with a software platform to capture, log, and analyze injection events (dose, timing, frequency) for patients managing chronic conditions requiring regular injectable therapy. The combined hardware-software architecture suggests a vertically integrated medical device product, with proprietary firmware and companion software that together generate longitudinal patient datasets.
The organization is structured as a product-stage medtech company with a leadership team spanning clinical (Chief Medical Officer Victor Villagra), commercial (Executive Vice President of Commercial Development Shawna Gvazdauskas), and operational functions (Director of Operations Aaron Townsend, Director of Software Development Emily Hart). Co-founders Richard Whalley (President) and Jamie Earl White (Board Member) provide continuity from the company's 2012 founding. Common Sensing has raised approximately $13.9 million across nine disclosed funding rounds between 2013 and 2021, anchored by Waterline Ventures and including a strategic corporate consortium of Philips, Sanofi Ventures, Qualcomm Ventures, Haselmeier, and New World Health, with later participation by Pleasant Bay Capital Partners.
The strategic investor composition indicates a partnership-led go-to-market model rather than direct-to-consumer distribution. By aligning with pharmaceutical manufacturers (Sanofi), drug delivery device makers (Haselmeier), and connected health platforms (Philips, Qualcomm), the company is positioned to commercialize through B2B channels — likely a combination of device sales, licensing, and data services to pharma and medtech partners — rather than selling directly to patients or providers. This channel strategy is consistent with the regulatory complexity of injectable drug delivery and the value of distribution through established healthcare players.
Common Sensing firmographics
Firmographics- Name
- Common Sensing
- Website
- https://common-sensing.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Common Sensing is a Cambridge-based medical technology company founded in 2012 that develops and manufactures data-driven hardware and software solutions for patients using injectable medicines, with strategic backing from Philips, Sanofi Ventures, Qualcomm Ventures, and other healthcare investors.
- Ownership category
- akta.pro rank
Common Sensing industry classification
Industry- Product category
- Connected Medical Devices / Diabetes Management
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Smart Insulin Pens & Connected Pen Caps (HLAHAHAD)
- akta.pro secondary industries
- Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM), Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH), Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)
Keywords
Where Common Sensing is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Common Sensing business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Online Gambling Services: Platform generates revenue through various gambling services including sports betting, live casino, slot games, poker, lottery, and other gaming activities. Revenue comes from player bets, house edge, and transaction fees.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Common Sensing product offering
Product offeringCore offering
Common Sensing develops and manufactures data-driven hardware and software solutions for people using injectable medicine. The company's connected-device hardware captures injection data from pen injectors, and its software platform logs, transmits, and visualizes that data to support patients, clinicians, and care programs managing injectable therapies such as insulin.
Differentiator
Problem solved
Functional benefit
Products and services
- Data-driven injectable-medicine monitoring hardware and software platform Connected medical-device hardware and companion software that monitor and record injectable medicine use, capturing dose-level data and making it available to patients, clinicians, and care programs managing injectable therapies such as insulin.
Companies that use Common Sensing
Customer profileSegments1 record
Ideal customer profiles3 records
Common Sensing technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Common Sensing partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and major.
- AFB GamingcoreGaming provider offering sportsbook and slot games. One of the featured providers on the platform with HOT and NEW status indicators.
- Pragmatic PlaycoreMajor slot and live casino provider featured prominently on the platform as a HOT provider.
- Evolution GamingcoreLeading live casino provider offering live dealer games including Baccarat, Sicbo, Dragon Tiger, and Roulette.
- PlaytechcoreProvider offering slot games and live casino content on the platform.
- AFC (Asian Football Confederation) / Sports PartnersmajorPartnership with major sports leagues including Premier League, La Liga, Bundesliga, Serie A, and Ligue 1 for sports betting content.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Common Sensing competitors and assessment
Company assessmentBroad incumbents
- Dexcom: Leader in continuous glucose monitoring with growing investment in diabetes dosing-decision ecosystems; adjacent competitor for diabetes-data mindshare and clinician workflow.
- Novo Nordisk (connected insulin pens): Markets NovoPen 6 and NovoPen Echo Plus — first-party connected insulin pens. Represents the pharma-embedded competitive alternative that retrofit caps must beat on cost or features.
- Eli Lilly (Tempo smart pen): Developed Tempo, a connected insulin pen platform integrated with its diabetes therapeutics; another pharma-first-party threat to independent smart-cap vendors.
- Insulet (Omnipod): Patch insulin pump maker pushing into automated dosing and connected injection alternatives; competes for the same provider and patient attention in insulin delivery.
- Sanofi (diabetes & connected care): Major insulin and biologics manufacturer and Common Sensing investor via Sanofi Ventures; represents the pharma distribution channel that could scale connected injection solutions.
- Medtronic (diabetes): Major diabetes device incumbent across pumps, CGM, and increasingly connected injection workflows; broader portfolio player that intersects with Common Sensing's dosing-data ambition.
Direct peers
- BioCorp: French medtech developing connected add-on devices and smart caps for pen injectors and inhalers; directly comparable on the drug-delivery connectivity and digital add-on thesis.
- Bigfoot Biomedical: Develops connected insulin pen caps and dosing-decision support for people with diabetes; the closest direct competitor to Common Sensing's smart-cap approach in the U.S. diabetes market.
Emerging players
- Amalgamated Medical (smart cap adjacent): Medical device distributor active in diabetes injection aids; relevant adjacent channel for retrofit connected device distribution.
Others
- Haselmeier: Pen injector manufacturer and Common Sensing investor; relevant as a strategic partner/customer whose platforms host compatible smart-cap integrations.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Common Sensing social profiles
Digital presenceCommon Sensing financial estimates
Financial estimateRevenue estimate
Valuation estimate
Common Sensing leadership team
Management profileNumber of profiles
Profiles6 records
Common Sensing funding detail
Funding detailFunding overview
Funding rounds9 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Common Sensing M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Common Sensing
What does Common Sensing do?
Common Sensing develops and manufactures data-driven hardware and software solutions for people using injectable medicine. The company's connected-device hardware captures injection data from pen injectors, and its software platform logs, transmits, and visualizes that data to support patients, clinicians, and care programs managing injectable therapies such as insulin.
When was Common Sensing founded?
Common Sensing was founded in 2012. It employs 11 to 50 people.
Where is Common Sensing based?
Common Sensing is headquartered in Cambridge, United States, in the North America region.
How does Common Sensing make money?
One revenue line is on record: online Gambling Services.
Who are Common Sensing's main competitors?
Broad incumbents on record are Dexcom, Novo Nordisk (connected insulin pens), Eli Lilly (Tempo smart pen), Insulet (Omnipod), Sanofi (diabetes & connected care) and Medtronic (diabetes). Direct peers are BioCorp and Bigfoot Biomedical. Amalgamated Medical (smart cap adjacent) is listed as an emerging player. Haselmeier is listed as an others.
Does Common Sensing have an API?
No public API is recorded for Common Sensing.
What industry is Common Sensing in?
Common Sensing's product category is Connected Medical Devices / Diabetes Management. Its primary akta.pro industry code is HLAHAHAD, Smart Insulin Pens & Connected Pen Caps, with a secondary code of HLAHAIAM, Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps). Its NAICS code is 334510 and its SIC code is 3845.